Clinical Trial Update: A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety of DSP-3077 given by unilateral intravitreal injection in adults with retinitis pigmentosa. The study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• DSP-3077 (DSP-3077)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: RECRUITING